FDA panel backs most experimental peptides, but legal path remains unclear

During a marathon July hearing, the FDA advisory committee voted in favor of six of seven peptide therapies, such as BPC-157, TB-500 and MOTS-c, despite internal scientific reservations. The recommendation does not automatically legalize production; the FDA must still assess the evidence before authorizing compounding pharmacies to create the compounds. Health Secretary Robert F. Kennedy Jr. has publicly pressed the agency to make the peptides available quickly, while legal analysts note that the standard rulemaking process could extend from several months to over a year.

An interim solution could involve placing the peptides on a “Category One” list, granting compounding pharmacies provisional permission while the formal rulemaking proceeds. Attorneys for the industry anticipate the FDA will pursue any expedited route, even if it invites lawsuits, whereas critics stress the need for safety data before widespread distribution. If approved, the drugs would require prescriptions and be supplied by specialty compounding pharmacies, not typical retail chains, likely causing a chaotic rollout. Experts caution that commercial hype outpaces clinical evidence, and the absence of accepted medical guidelines leaves many physicians hesitant to prescribe these peptides.